By Hadley Gavin
Boosting testosterone levels through testosterone therapy can be very beneficial for older people. It has been proven to improve mood in chronic disease patients and may help increase bone density. However, there are some risks involved. It is important to be aware of these risks before beginning testosterone therapy. If you have heart problems or are at high risk for prostate cancer, it may be best to wait until your condition is under control.
The use of testosterone therapy is growing in the United States. The Department of Veterans Affairs has reported that over 1,200 Veterans have used testosterone therapy. However, there have also been claims of heart attacks and strokes. It is important to note that testosterone therapy should not be used to treat depression. There are psychotropic medications that are more effective at boosting mood-related symptoms.
Testosterone therapy can be administered by injection or through patches. It can be used to treat both sexual dysfunction and infertility. It can also help increase bone mass and improve bone strength. However, it has been reported that testosterone therapy can increase the risk of cardiovascular problems and prostate problems. It is important to ask questions before beginning testosterone therapy under the care of certified local ED physicians. Whether or not it is right for you will depend on a number of factors.
Testosterone is a male sex hormone that affects the production of red blood cells, muscle size and strength, and bone mass. Testosterone can be found naturally in men, but it can also be injected into the body, absorbed through the skin, or implanted in soft tissues.
Testosterone replacement therapy is approved for treating primary hypogonadism in men. It can be administered through a patch, injection, or gel. It is used to treat a number of male conditions, including sexual dysfunction, sex loss, infertility, and anemia.
Increasing awareness about the disease and availability of therapies are the two main factors that are driving growth in the TRT market. The market is expected to reach $3.8 billion globally by 2022. The rising prevalence of hypogonadism in the aging population is also driving market growth.
Testosterone therapy has been associated with increased short-term risk for venous thromboembolism (VTE). A study by Baillargeon et al found that testosterone therapy was associated with a higher incidence of VTE in men with no history of hypogonadism. The study included 7500 VTE events. The study was based on a case-crossover design that assumed transient exposures. The association was more pronounced in younger men. The study included 374 men who were prescribed testosterone at least 12 months before the onset of VTE. The study also found that testosterone therapy was associated with an increase in the risk of non-calcified plaque in blood vessels supplying the heart. These plaques can narrow arteries, increasing the risk of clotting.
Testosterone can also be used to treat men with low libido and low sexual desire. The study found that testosterone therapy improved sexual function and mood. However, testosterone therapy was not effective in improving memory in men with age-related memory problems.
